- Home
- CLLS vs SCPH Comparison
CLLS vs SCPH Comparison
Compare CLLS & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- SCPH
- Stock Information
- Founded
- CLLS 1999
- SCPH 2013
- Country
- CLLS France
- SCPH United States
- Employees
- CLLS 216
- SCPH N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- SCPH Health Care
- Exchange
- CLLS Nasdaq
- SCPH Nasdaq
- Market Cap
- CLLS 148.1M
- SCPH 179.6M
- IPO Year
- CLLS 2007
- SCPH 2017
- Fundamental
- Price
- CLLS $1.48
- SCPH $3.28
- Analyst Decision
- CLLS Buy
- SCPH Strong Buy
- Analyst Count
- CLLS 3
- SCPH 2
- Target Price
- CLLS $7.00
- SCPH $15.00
- AVG Volume (30 Days)
- CLLS 235.1K
- SCPH 426.6K
- Earning Date
- CLLS 11-04-2024
- SCPH 03-12-2025
- Dividend Yield
- CLLS N/A
- SCPH N/A
- EPS Growth
- CLLS N/A
- SCPH N/A
- EPS
- CLLS N/A
- SCPH N/A
- Revenue
- CLLS $36,042,000.00
- SCPH $30,278,000.00
- Revenue This Year
- CLLS $387.77
- SCPH $172.64
- Revenue Next Year
- CLLS $11.14
- SCPH $131.43
- P/E Ratio
- CLLS N/A
- SCPH N/A
- Revenue Growth
- CLLS 46.96
- SCPH 303.87
- 52 Week Low
- CLLS $1.41
- SCPH $3.08
- 52 Week High
- CLLS $3.38
- SCPH $6.54
- Technical
- Relative Strength Index (RSI)
- CLLS 38.66
- SCPH 41.49
- Support Level
- CLLS $1.65
- SCPH $3.27
- Resistance Level
- CLLS $2.23
- SCPH $3.59
- Average True Range (ATR)
- CLLS 0.18
- SCPH 0.19
- MACD
- CLLS -0.03
- SCPH -0.00
- Stochastic Oscillator
- CLLS 8.54
- SCPH 2.08
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.